提名人成都欧林生物科技股份有限公司董事会,现提名段宏 为成都欧林生物科技股份有限公司第七届董事会独立董事候选 人,并已充分了解被提名人职业、学历、职称、详细的工作经历、 全部兼职、有无重大失信等不良记录等情况。被提名人已书面同 意出任成都欧林生物科技股份有限公司第七届董事会独立董事 候选人(参见该独立董事候选人声明)。提名人认为,被提名人 具备独立董事任职资格,与成都欧林生物科技股份有限公司之间 不存在任何影响其独立性的关系,具体声明并承诺如下: 科创板上市公司独立董事提名人声明与承诺 一、被提名人具备上市公司运作的基本知识,熟悉相关法律、 行政法规、规章及其他规范性文件,具有五年以上法律、经济、 会计、财务、管理等履行独立董事职责所必需的工作经验。 被提名人已经参加培训并取得证券交易所认可的相关培训 证明材料。 二、被提名人任职资格符合下列法律、行政法规和部门规章 的要求: (一)《中华人民共和国公司法》等关于董事任职资格的规 定: (二)《中华人民共和国公务员法》关于公务员兼任职务的 规定(如适用): (三)中国证监会《上市公司独立董事管理办法》、上海证 券交易所自律监管规则以及公司章程有关独立董事任职资 ...

科创板 本人 陈正旭,已充分了解并同意由提名人成都欧林生物科 技股份有限公司董事会提名为成都欧林生物科技股份有限公司 第七届董事会独立董事候选人。本人公开声明,本人具备独立董 事任职资格,保证不存在任何影响本人担任成都欧林生物科技股 份有限公司独立董事独立性的关系,具体声明并承诺如下: 一、本人具备上市公司运作的基本知识,熟悉相关法律、行 政法规、部门规章及其他规范性文件,具有五年以上法律、经济 会计、财务、管理等履行独立董事职责所必需的工作经验。 二、本人任职资格符合下列法律、行政法规和部门规章以及 公司规章的要求: (一)《中华人民共和国公司法》等关于董事任职资格的规 定; (二)《中华人民共和国公务员法》关于公务员兼任职务的 规定(如适用); (三)中国证监会《上市公司独立董事管理办法》和上海证 券交易所自律监管规则有关独立董事任职资格和条件的相关规 定; (四)中共中央纪委、中共中央组织部《关于规范中管干部 辞去公职或者退(离)休后担任上市公司、基金管理公司独立董 事、独立监事的通知》的规定(如适用); (十)其他法律法规、部门规章、规范性文件和上海证券交 易所规定的情形。 三、本人具备独立性,不属于 ...

（一） 股东大会类型和届次 2025年第一次临时股东大会 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 证券代码：688319 证券简称：欧林生物 公告编号：2025-029 成都欧林生物科技股份有限公司 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 7 月 30 日 13 点 00 分 召开地点：成都高新区天欣路 99 号公司会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 7 月 30 日 至2025 年 7 月 30 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年7月30日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 东大会召开当日的 ...

证券代码：688319 证券简称：欧林生物 公告编号：2025-026 （一）审议通过了《关于取消公司监事会并修订<公司章程>的议案》 监事会认为：根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《关于新公司法配套制度规则实施相关过渡期安排》、《上市公司章程指引（2025 年修订）》（以下简称"《章程指引》"）等相关规定，并结合公司第六届监事 会任期届满的实际情况，公司拟不再设置监事会及监事，原监事会部分职权将由 董事会审计委员会承接，《成都欧林生物科技股份有限公司监事会议事规则》相 应废止，《成都欧林生物科技股份有限公司章程》（以下简称"《公司章程》"） 以及公司各项规章制度中涉及监事会、监事的规定亦不再适用。 同时，依据《公司法》《章程指引》《上海证券交易所科创板股票上市规则》 等规定及公司实际情况，公司拟对《公司章程》进行修订。上述调整旨在进一步 完善公司治理结构，满足相关法律法规与规范要求。 具体内容详见公司同日在上海证券交易所网站(www.sse.com.cn)披露的《成 都欧林生物科技股份有限公司关于取消监事会、修订<公司章程>及制定、修订和 废止部分公司治理制度的公告》（公告编号：20 ...

Core Viewpoint - On July 7, a total of 30 listed companies had their restricted shares unlocked, with a total market value of approximately 15.657 billion yuan [1] Summary by Category Restricted Share Unlocking - Xiamen Xinda (000701) had 4.5378 million shares unlocked under equity incentive restrictions - Qianjiang Motorcycle (000913) had 117,500 shares unlocked under equity incentive restrictions - Shenhuo Co. (000933) had 5.1992 million shares unlocked under equity incentive restrictions - Xiamen Xiangyu (600057) had 28.3365 million shares unlocked under equity incentive restrictions - Inner Mongolia First Machinery (600967) had 20,630 shares unlocked under equity incentive restrictions - Bowei Alloys (601137) had 720,000 shares unlocked under equity incentive restrictions - Kebo Da (603786) had 1.5424 million shares unlocked under equity incentive restrictions - Jianke Co. (301115) had 90,000 shares unlocked under equity incentive restrictions - Jinhai Biological (002688) had 6.411 million shares unlocked under equity incentive restrictions - Tiantian Technology (300587) had 2.1044 million shares unlocked under equity incentive restrictions - Shengbang Co. (301233) had 994,200 shares unlocked under pre-issue restrictions - Zhonglan Environmental (300854) had 797,500 shares unlocked under equity incentive restrictions - Bidetech (605298) had 1.23 million shares unlocked under equity incentive restrictions - Tian'ao Electronics (002935) had 1.8468 million shares unlocked under equity incentive restrictions - Zhongyi Technology (301208) had 510,000 shares unlocked under pre-issue restrictions - Dielian Technology (300679) had 28,710 shares unlocked under equity incentive restrictions - Xishanghai (605151) had 544,000 shares unlocked under equity incentive restrictions - Dingsheng New Materials (603876) had 324,000 shares unlocked under equity incentive restrictions - Keli Sensor (603662) had 118,800 shares unlocked under equity incentive restrictions - Keri Technology (002957) had 451,100 shares unlocked under equity incentive restrictions - Puri Eye Hospital (301239) had 78.8296 million shares unlocked under pre-issue restrictions - Wuzhou Medical (301234) had 49.572 million shares unlocked under pre-issue restrictions - Sanwei Tiandi (301159) had 30.4475 million shares with extended lock-up period unlocked - Hush Silicon Industry (688126) had 11.3603 million shares unlocked - Junshi Biosciences (688180) had 1.8452 million shares unlocked - Olin Bio (688319) had 224,700 shares unlocked - Guoxin Technology (688262) had 71.6493 million shares unlocked - Yahui Pharmaceutical (688176) had 129 million shares unlocked - Lingyun Optical (688400) had 224 million shares unlocked - Aobi Zhongguang (688322) had 34.0322 million shares unlocked [1]

Core Viewpoint - Oulin Bio is accelerating its expansion efforts by raising 175 million RMB to invest in the technological transformation of its vaccine R&D and production base to enhance production efficiency and product quality in response to growing market demand [2][3] Group 1: Fundraising and Investment - Oulin Bio plans to raise a total of 175 million RMB through a simplified procedure for issuing ordinary shares, which will be invested in a vaccine R&D production base technological transformation project [2][3] - The total investment for the vaccine R&D production base technological transformation project is 290 million RMB, with a planned implementation period of four years [3] - The project will upgrade production workshops for key products, including the tetanus workshop, polysaccharide workshop, and freeze-drying workshop, and will involve technical upgrades to related facilities and equipment [3] Group 2: Company Background and Performance - Founded in 2009, Oulin Bio specializes in the R&D, production, and sales of human vaccines and was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board in 2021 [2][5] - The company has achieved steady growth, with its core product, the adsorbed tetanus vaccine, maintaining a leading market share in China, generating sales revenue of 535.8 million RMB in 2024, a year-on-year increase of 15.7% [5] - In the first quarter of 2025, Oulin Bio continued its growth trend, achieving revenue of 87.49 million RMB, a year-on-year increase of 23.58%, while reducing net loss to 7.074 million RMB from 26 million RMB in the same period last year [6] Group 3: R&D Investment and Innovation - Oulin Bio has consistently invested in innovation, with total R&D expenses reaching 470 million RMB from 2020 to 2024 [6] - The company has a strong focus on developing a complete innovation pipeline centered around the "super bacteria vaccine" strategy, particularly in the field of antibiotic-resistant bacteria vaccines [4] - As of 2024, Oulin Bio has 136 R&D personnel, accounting for 28.94% of its total workforce, and has obtained a total of 82 invention patents [6]

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. reported on the usage of funds raised from its initial public offering, detailing the total amount raised, the current balance, and the allocation of these funds for various projects [1][2][3]. Fundraising Overview - The company raised a total of RMB 400,436,400.00 from the issuance of 40,530,000 shares at RMB 9.88 per share, with a net amount of RMB 358,837,273.38 after deducting issuance costs [1]. - As of March 31, 2025, the remaining balance of the raised funds is RMB 100,390,120.43, which accounts for 27.98% of the net amount raised [8]. Fund Storage Situation - The funds are stored in two bank accounts: - RMB 39,859,763.12 at China Merchants Bank - RMB 60,530,357.31 at Industrial Bank, totaling RMB 100,390,120.43 [2]. Actual Usage of Funds - The company has utilized RMB 27,752.20 million of the raised funds, with the following annual breakdown: - 2021: RMB 1,998.69 million - 2022: RMB 9,931.96 million [9]. - The company has adjusted the allocation of funds, redirecting RMB 10,278.30 million initially intended for vaccine projects to clinical research projects [3]. Temporary Idle Funds Management - The company has engaged in cash management for temporarily idle funds, with a maximum daily balance not exceeding RMB 30 million. The investment returns from cash management in 2021, 2022, and 2023 were RMB 3.4968 million, RMB 7.1798 million, and RMB 8.1850 million, respectively [5][6][7]. Economic Benefits from Investment Projects - The report includes a table detailing the economic benefits realized from the investment projects, although specific figures are not provided in the summary [9][12].

Meeting Overview - The sixth session of the Supervisory Board of Chengdu Olin Biological Technology Co., Ltd. was held on June 25, 2025, with all three supervisors present, confirming the legality and validity of the meeting [1]. Resolutions Passed - The Supervisory Board approved the proposal regarding the results of the stock issuance to specific targets, affirming the legality and compliance of the issuance process [2]. - The signing of a subscription agreement with specific targets was approved, ensuring no harm to the interests of the company and its shareholders [2]. - The authenticity, accuracy, and completeness of the fundraising prospectus for the stock issuance were confirmed, with no misleading statements or omissions [2]. - The revised plan for the stock issuance was approved, aligning with relevant laws and the company's specific circumstances [2][4]. - The analysis report for the stock issuance plan was deemed compliant with legal regulations [4]. - The feasibility analysis report for the use of raised funds was approved, confirming its alignment with legal requirements [5]. - The report on the use of previously raised funds as of March 31, 2025, was approved, with an audit report from Zhongqin Wanxin Accounting Firm [5]. - The detailed report on non-operating gains and losses for the last three years and one quarter was approved, with an audit report confirming its compliance [6]. - The internal control evaluation report for the first quarter of 2025 was approved, reflecting the actual internal control situation [7]. - The measures to mitigate the dilution of immediate returns from the stock issuance were approved, along with commitments from relevant parties [8]. - The explanation regarding the fundraising's alignment with technology innovation was approved, confirming its compliance with legal regulations [9]. - The establishment of a dedicated account for the raised funds and the authorization to sign a regulatory agreement was approved, ensuring proper management of the funds [9].

Core Viewpoint - Chengdu Olin Biological Technology Co., Ltd. is issuing A-shares to specific investors, which may dilute immediate returns, and the company has proposed measures to mitigate this impact [1][5]. Financial Impact Analysis - The company analyzed the impact of the stock issuance on key financial metrics under three scenarios for 2025 net profit compared to 2024: - Scenario 1: 10% increase in net profit results in net profit of 22.83 million yuan and basic earnings per share (EPS) of 0.0558 yuan [3]. - Scenario 2: Net profit remains unchanged at 20.76 million yuan, leading to basic EPS of 0.0507 yuan [4]. - Scenario 3: 10% decrease in net profit results in net profit of 18.68 million yuan and basic EPS of 0.0457 yuan [4]. Necessity and Reasonableness of the Issuance - The funds raised will be used for the "Vaccine R&D Production Base Technology Renovation Project," which aligns with the company's core business and development strategy [5][6]. Company’s Resource and Capability Assessment - The company has a stable management team with extensive experience in the biopharmaceutical industry and is committed to continuous talent development [6][7]. - The R&D team has over ten years of experience in vaccine development, focusing on both traditional and innovative vaccines [7][8]. Measures to Mitigate Dilution of Immediate Returns - The company will maintain stable growth in its main business and accelerate the investment progress of the fundraising projects to enhance profitability [9]. - It will strengthen fundraising management to ensure compliance and effective use of raised funds [11]. - The company plans to improve its profit distribution policy to optimize investor returns [12][13]. Commitments from Major Stakeholders - The controlling shareholders and actual controllers have committed to ensuring the fulfillment of measures to mitigate the dilution of immediate returns [14][15]. - The board of directors and senior management have also made commitments to protect company interests and ensure compliance with regulations [15][16].

关于以简易程序向特定对象发行人民币普通股 证券代码：688319 证券简称：欧林生物 公告编号：2025-022 成都欧林生物科技股份有限公司 （A 股）股票预案（修订稿）披露的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都欧林生物科技股份有限公司（以下简称"公司"）于 2024 年 10 月 29 日召开第六届董事会第十七次会议审议通过了《关于公司以简易程序向特定对象 发行股票预案的议案》等相关议案，于 2025 年 6 月 25 日召开第六届董事会第二 十一次会议通过了《关于公司以简易程序向特定对象发行股票竞价结果的议案》 《关于公司与特定对象签署附生效条件的股份认购协议的议案》等相关议案。 根据公司 2023 年年度股东大会及 2024 年年度股东大会的授权，本次修订预 案无需另行提交公司股东大会审议。 本次以简易程序向特定对象发行股票的预案披露不代表审核、注册部门对于 本次发行股票相关事项的实质性判断、确认或批准，预案所述本次发行相关事项 的生效和完成尚需上海证券交易所审核通过，并经中国证券监督管 ...